Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Assets: 2019-2024

Historic Current Assets for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $510.3 million.

  • Kymera Therapeutics' Current Assets fell 7.11% to $528.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $528.3 million, marking a year-over-year decrease of 7.11%. This contributed to the annual value of $510.3 million for FY2024, which is 25.89% up from last year.
  • As of FY2024, Kymera Therapeutics' Current Assets stood at $510.3 million, which was up 25.89% from $405.3 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Current Assets high stood at $510.3 million for FY2024, and its period low was $302.3 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $419.4 million (2022), whereas its average is $445.0 million.
  • Per our database at Business Quant, Kymera Therapeutics' Current Assets surged by 225.64% in 2020 and then dropped by 7.06% in 2022.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Current Assets stood at $302.3 million in 2020, then spiked by 49.26% to $451.3 million in 2021, then declined by 7.06% to $419.4 million in 2022, then declined by 3.36% to $405.3 million in 2023, then increased by 25.89% to $510.3 million in 2024.